Vermillion Biomarker Panel Potential Aid In The Diagnosis Of Peripheral Artery Disease

Vermillion,
Inc. (Nasdaq: VRML), a molecular diagnostics company, presented data from a
study providing further confirmation that the Company's multi-protein
biomarker panel may aid in the diagnosis of peripheral artery disease
(PAD). The research suggests that such a panel may be useful in alerting
physicians to the possibility of PAD in patients who might otherwise be
undiagnosed. Results of the study were presented as a poster at the
American College of Cardiology 57th Annual Scientific Session.


Working in collaboration with researchers at Stanford University,
Vermillion intends to develop a blood test for the diagnosis of PAD. In
March, the Company entered into an exclusive license agreement with the
University to develop and commercialize a biomarker panel used to assess
the risk of the disease, which is estimated to affect up to 12 million
Americans and can result in severe complications, including amputation,
heart attack, stroke and even death.



"Few studies have explored combinations of protein markers to create a
distinct biomarker panel score to stratify individuals according to their
risk of having PAD. However, our study successfully accomplishes this by
discovering a multi-marker panel that could significantly aid in
identifying such patients," said Eric T. Fung, M.D., Ph.D., Chief
Scientific Officer of Vermillion. "We are pleased with these findings and
are developing a clinical trial protocol to generate data for support of a
submission to the U.S. Food and Drug Administration (FDA)."



The study was conducted to develop an index score based on a
combination of proposed biomarkers for PAD, including two based on
proteomic discovery. A total of 540 patients were analyzed in the study.
These patients were randomly selected from the ongoing GenePAD trial, which
comprises individuals undergoing coronary angiography at Stanford
University or Mount Sinai Medical Centers. The company expects to publish
results from this study in a peer-reviewed medical journal.



About Vermillion



Vermillion, Inc. is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with
its prestigious scientific collaborators, has diagnostic programs in
oncology, hematology, cardiology and women's health. Vermillion is based in
Fremont, California. Additional information about Vermillion can be found
on the Web at vermillion.



Forward Looking Statements
















This news release contains forward-looking statements that involve
significant risks and uncertainties, including statements regarding
Vermillion's plans, objectives, expectations and intentions. These
forward-looking statements are based on Vermillion's current expectations.
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for such forward-looking statements. In order to comply with the
terms of the safe harbor, Vermillion notes that a variety of factors could
cause actual results and experience to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. There are no guarantees that Vermillion will succeed in its
efforts to commercialize PAD diagnostic tests in 2008 or during any other
period of time. Factors that could cause actual results to materially
differ include but are not limited to: (1) uncertainty in obtaining
intellectual property protection for inventions made by Vermillion; (2)
unproven ability of Vermillion to discover, develop, and commercialize PAD
diagnostic products based on findings from its disease association studies;
(3) unproven ability of Vermillion to discover or identify new protein
biomarkers and use such information to develop PAD diagnostic products; (4)
uncertainty as to whether Vermillion will be able to obtain any required
regulatory approval of its PAD diagnostic products; (5) uncertainty of
market acceptance of its PAD diagnostic products, including the risk that
its products will not be competitive with products offered by other
companies, or that users will not be entitled to receive adequate
reimbursement for its products from third party payors such as private
insurance companies and government insurance plans; and (6) other factors
that might be described from time to time in Vermillion's filings with the
Securities and Exchange Commission. All information in this press release
is as of the date of the release, and Vermillion expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in Vermillion's expectations or
any change in events, conditions or circumstances on which any such
statement is based, unless required by law.


Vermillion, Inc.

vermillion